Bicycle Therapeutics appoints Rolf H. Günther, M.D., Ph.D. as CEO
Dr. Günther has over 21 years of pharmaceutical industry experience with an extensive background in drug development, biologics and speciality pharmaceuticals. He previously served as CEO and COO of Affimed, a monoclonal antibody company, since 2004 and has successfully developed its clinical product portfolio in oncology. Dr. Günther will continue to be engaged as COO in Affimed in a part time position until August this year. He held the position of VP and General Manager of the Critical Care business unit of Aventis Behring, which he joined as VP Global Clinical Research in 1996, and was responsible for successful drug approvals in the US and Europe.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.